Day 1  
June 16, 2016

07:30-08:45 Registrations

**Appia**

[conferenceseries.com](http://conferenceseries.com) 08:45-09:00

**Opening Ceremony**

**Keynote Forum**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-09:05</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td>09:05-09:35</td>
<td>Development of the full length single chain gp120-CD4 (FLSC), a novel vaccine for HIV prevention</td>
<td>Timothy R Fouts, Profectus Biosciences Inc., USA</td>
</tr>
<tr>
<td>09:35-10:05</td>
<td>Vaccines moving beyond the next frontier</td>
<td>Rene Labatut, Sanofi Pasteur, France</td>
</tr>
</tbody>
</table>

**Networking & Refreshments Break 10:05-10:25 @ Foyer area**

10:25-10:55 VGX-3100 drives regression of HPV16/18 CIN2/3 and robust cellular immune responses in blood and cervical tissue in a blinded, randomized, placebo-controlled phase 2b study  
Prakash Bhuyan, Inovio Pharmaceuticals, USA

**Track 1: Cancer Vaccines**

**Track 2: Vaccine Products and Delivery Technologies**

**Track 3: Vaccine Research and Development**

**Track 4: Vaccines for Respiratory Infections**

**Track 5: HIV Vaccines**

**Track 6: Veterinary vaccines**

**Session Chair:** Timothy R Fouts, Profectus Biosciences Inc., USA  
**Session Co-chair:** Qingsheng Li, University of Nebraska-Lincoln, USA

**Group Photo**

**Session Introduction**

10:55-11:15 Pre-clinical evaluation of the therapeutic application of a vaccine targeting the 12 protease cleavage sites  
Ma Luo, University of Manitoba, Canada

11:15-11:35 Distinct transcriptome profiles of Gag-specific CD8+ T cells temporally correlated with the protection elicited by live attenuated SIV  
Qingsheng Li, University of Nebraska-Lincoln, USA

11:35-11:55 TAT, the forgotten target that could help to cure from HIV  
Erwann P Loret, ETRAV Laboratory, France

11:55-12:15 Community engagement during the Ebola vaccine trial in Guinea  
Godwin Enwere, World Health Organization, Switzerland

12:15-12:35 Pre-clinical toxicology considerations in vaccine  
Nabil Al-Humadi, Food and Drug Administration, USA

**Lunch Break 12:35-13:25 @ Restaurant**

13:25-13:45 Codon harmonization, a step beyond optimization to capture the natural rhythm of protein translation  
Bettina Werle, Bioaster, France

13:45-14:05 Development of lipid based oral vaccine formulations  
Sarah Margaret Hook, University of Otago, New Zealand

14:05-14:25 Viral vectored genetic vaccines: Current status and future perspectives  
Antonella Folgori, Reithera SRL, Italy

14:25-14:45 Active immunization against proprotein convertase subtilisin/kexin type 9 (PCSK9): A new strategy to control hyperlipidemia  
Gunter Staffler, AFFiRiS AG, Austria

14:45-15:05 Development of a production and purification platform for virus like particles (VLP) vaccine candidates: A case study  
Anissa Boumil-Courtade, Merck Life Science, France

15:05-15:25 MATS: Global coverage estimates for 4CMenB, a novel multi-component meningococcal B vaccine  
Duccio Medini, GSK Vaccines, Italy

**Networking & Refreshments Break 15:25-15:45 @ Foyer area**

15:45-16:05 Implementing a randomized control trial (RCT) in the context of an Ebola epidemic  
Godwin Enwere, World Health Organization, Switzerland

16:05-16:25 Vaccination with self-adjuvanted protein nanoparticles provides protection against lethal influenza challenge  
Peter Burkhard, Alpha-O Peptides AG, Switzerland
16:25-16:45 Plant expression platforms for vaccine production
Kathleen Hefferon, Cornell University, USA

16:45-17:05 What do Lebanese women know about cervical cancer and human papillomavirus prevention? A report on awareness levels in urban communities
Jacques Choucair, Saint Joseph University, Lebanon

17:05-17:20 Isolation and characteristics identification of bovine rotaviruses from vaccinated dairy calves in Morocco
Ennima Imane, University Mohammed V of Rabat, Morocco

17:20-17:35 Bluetongue virus (BTV) serological survey and evidence of emergent BTV-8 serotype in Morocco
Kamar Drif, Institut Agronomique et Veterinaire Hassan II, Morocco

17:35-17:50 Evaluation of the protection conferred by an attenuated vaccine (Mass-type H120) of avian infectious bronchitis against a new emerging Italy 02 genotype in Moroccan broiler chickens
Khadija Khataby, University Hassan II of Casablanca, Morocco

Panel Discussion

Day 2  June 17, 2016

Appia

Keynote Forum

09:00-09:30 Towards affordable conjugate vaccines: Efficient chemistry and low cost carrier protein
Andrew Lees, Fina Biosolutions LLC, USA

09:30-10:00 Human vaccines and vaccination for non-infectious diseases
Giulio Filippo Tarro, Foundation T. & L. de Beaumont Bonelli for Cancer Research, Italy

Networking & Refreshments Break 10:00-10:20 @ Foyer area

10:20-10:50 Challenges and dilemmas about vaccines against the herpesviruses: The case of EBV
Emmanuel Drouet, Université Grenoble-Alpes, France

Track 7: Vaccines against Infectious diseases
Track 8: Viral Vaccines
Track 9: Bacterial Vaccines
Track 10: Childhood Vaccines
Track 11: Hepatitis Vaccines
Track 12: Toxoid Vaccines

Session Chairs: Giulio Filippo Tarro, Foundation T. & L. de Beaumont Bonelli for Cancer Research, Italy
Andrew Lees, Fina Biosolutions LLC, USA

10:50-11:10 Rapid development of an oral Zika virus vaccine
Sean N Tucker, Vaxart Inc., USA

11:10-11:30 Preclinical development of HeV-sG as a vaccine and m102.4 as a post exposure prophylaxis against henipavirus infections
Timothy R Fouts, Profectus Bio-Sciences, USA

11:30-11:50 Measles: Need for continued vaccination and novel vaccines post virus eradication
S Louise Cosby, Agri-Food and Biosciences Institute, UK

11:50-12:10 Evaluation of genetic stability of transgenes in vaccine
Ali Azizi, Sanofi Pasteur, Canada

12:10-12:30 Process development for pneumococcal protein vaccines based on recombinant pneumococcal surface protein A (PspA) and hybrids of PspA and pneumolysin toxoid
Viviane Maimoni Goncalves, Instituto Butantan, Brazil

Lunch Break 12:30-13:20 @ Restaurant

13:20-13:40 The key person influences flu vaccination among health workers: Perspective study of social network
Xiaoning Hao, China National Health Development Research Center, China

13:40-14:00 Pneumococcal conjugate vaccine: Use of pneumococcal surface protein A (PspA) as carrier
Giovana Cappio Barazzone, Instituto Butantan, Brazil

14:00-14:20 Construction and immunological study on recombinant multi-epitope adenovirus vaccine for influenza virus
Hui-jun Lu, Changchun Veterinary Institute of CAAS, China

14:20-14:40 Pneumococcal inactivated whole cell vaccine: Development of the production process
Viviane Maimoni Goncalves, Instituto Butantan, Brazil

14:40-15:00 Knowledge, attitude and practices and influencing factors related to seasonal influenza vaccination among healthcare workers in Qingdao, China, 2013-14: A prospective cohort study
Xiaoning Hao, China National Health Development Research Center, China

15:00-15:20 Polio outbreak review in the Middle East and polio immunization mop-up campaigns in the Lebanese/Syrian refugees' context and post campaign results
Randa Hamadeh, Ministry of Public Health, Lebanon
15:40-16:00 Prevalence of tuberculin negativity after BCG vaccination in the under five Saudi children and the need for revaccination
Fahad Saleh Al-Tayyeb, King Abdulaziz Medical City, KSA

16:00-16:20 Vaccination of hepatitis B in healthy adults: Effect of sex and age, two protocols of revaccination in non-responders
Jacques Choucair, Saint Joseph University, Lebanon

Panel Discussion
Breakout
Cassia Meeting Room

Workshop on Revisiting HIV inactivation, elite controllers, immunogenetics and HIV therapeutic vaccines
Session Chairs: Barbara Ensoli, National AIDS Center-Istituto Superiore di Sanità, Italy
Felipe Garcia Alcaide, Hospital Clinic de Barcelona, Spain

09:00-09:30 Expanding the findings of RV144 to South Africa: P5 initiative
Glenda Gray, South African Medical Research Council, South Africa

09:30-10:00 Therapeutic vaccination with Tat restores immune homeostasis, promotes proviral DNA decay and induces cross-clade neutralizing antibodies in patients on HAART: Results from phase II clinical trials in Italy and South Africa
Barbara Ensoli, National AIDS Center-Istituto Superiore di Sanità, Italy

10:20-10:50 Current strategies for HIV remission: The role of therapeutic vaccines
Felipe Garcia Alcaide, Hospital Clinic de Barcelona, Spain

10:50-11:20 Synthetic DNA vaccines for difficult mucosal viruses including HIV
Jean D. Boyer, Inovio Pharmaceuticals Inc., USA

11:20-11:50 Potential development of inactivated HIV-1 transmitted/founder virus (T/F) vaccine
Adan Rios, PhotolImmune Biotechnology Inc., USA

11:50-12:20 Discussion
Lunch Break 12:20-13:20 @ Restaurant

Session Chairs: Marc H.V. Van Regenmortel, Biotechnology School of the University of Strasbourg, France
Eric Sandstrom, Karolinska Institutet, Sweden

13:20-13:50 HIV vaccine development: Is a moral wrong occurring?
Mike King, University of Otago, New Zealand

13:50-14:20 Reverse HIV vaccinology failed because it has no sound theoretical basis in the case of this virus
Marc H.V. Van Regenmortel, Biotechnology School of the University of Strasbourg, France

14:20-14:50 HIV replication is suppressed by CD8+ T-cell HIV suppressive activity
Eric Sandstrom, Karolinska Institutet, Sweden

14:50-15:20 Concerns in the planning of therapeutic immunizations in HIV infected patients aiming to harness HLA E restricted CD8+T-cell HIV suppressive activity
Eric Sandstrom, Karolinska Institutet, Sweden

15:40-16:10 Multiple immunogenetic aspects in susceptibility to HIV-1 infection progression toward AIDS and rational vaccine design
Massimo Amicosante, University of Rome, Italy

EVACC 01 Role of insulin like growth factor-1 derived from macrophages in an influenza vaccine induced humoral immune response
Jae-Hwan Nam, Catholic University of Korea, South Korea

EVACC 02 Visualization of immune response to hepatitis B vaccination by in vivo small animal imaging
Hyewon Youn, Seoul National University, South Korea

EVACC 03 Development immunogen for protection against PRRSV infection using Korean isolates ORF5 protein expression using baculovirus expression system
Sun Shin Yi, Soonchunhyang University, South Korea

EVACC 04 Vaccine potentials of excretory-secretory antigens of 4 week old juveniles against Fasciola gigantica in mice
Narin Changklongma, Burapha University, Thailand

EVACC 05 Vaccine potentials of recombinant mature cathepsin L1H against Fasciola gigantica in mice
Pooman Kuekhai, Burapha University, Thailand

EVACC 06 Characterization and vaccination of the cytosolic Fasciola gigantica superoxide dismutase
Wipaphorn Jaikua, Mahidol University, Thailand

EVACC 07 Study for manufacture and establishment of 1st national standard material for cell derived Japanese encephalitis vaccine (Beijing strain)
Ji Young Hong, National Institute of Food and Drug Safety Evaluation, Korea
Histone deacetylase 10 (HDAC 10) deacetylates Foxp3 and modulates its stability
Suna Gu, Chonbuk National University, Republic of Korea

In silico design of epitope based peptide vaccine against virulent strains of HN-Newcastle disease virus (NDV) in poultry species
Marwa Mohamed Osman, Africa City of Technology, Sudan

Session Chair: Emmanuel Drouet, Université Grenoble-Alpes, France
Session Co-Chair: Sheikh Mohammad Fazle Akbar, Toshiba General Hospital, Japan

10:00-10:20 Vaccines for pregnant women - challenges and opportunities for harmonized safety monitoring
Sonali Kochhar, Global Healthcare Consulting, India

10:20-10:40 Exploiting a high dose murine challenge model for HSV to identify potential DNA prime subunit boost vaccine strategies that could be translated to human clinical trials
Timothy R Fouts, Profectus Biosciences Inc., USA

11:00-11:20 Operational experience and lessons learned on influenza vaccination post-authorization safety studies
Ombretta Palucci, Quintiles, Switzerland

11:20-11:40 Post-marketing surveillance of BCG vaccination
Ruwen Jou, Tuberculosis Research Center at Centers for Disease Control, Taiwan

11:40-12:00 Novel vaccine adjuvants for animal infectious diseases
Jishu Shi, Kansas State University, USA

12:00-12:20 Emerging market challenges: Development of a thermostable and immunologically active solid HPV vaccine formulation
Ramesh Chintala, Merck & Co. Inc., USA

13:10-13:30 Immunogenicity of VLP forming baculoviral DNA vaccine
Young Bong Kim, Konkuk University, Republic of Korea

13:30-13:50 Targeting TLR9 and TLR21 to develop vaccine adjuvant for different species
Tsung-Hsien Chuang, National Health Research Institutes, Taiwan

13:50-14:10 Therapeutic vaccines for treatment of allergic and autoimmune diseases
Zhikang Peng, University of Manitoba, Canada

14:10-14:30 Therapeutic vaccines against chronic hepatitis-B virus and related complications
Sheikh Mohammad Fazle Akbar, Toshiba General Hospital, Japan